112257-22-4

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl2-(piperazin-1-yl)acetate is used as an intermediate in the synthesis of various drugs and biologically active compounds for its ability to facilitate the production of pharmaceuticals with desired therapeutic properties.
Used in Chemical Research:
Tert-butyl2-(piperazin-1-yl)acetate serves as a valuable building block in organic synthesis, enabling researchers to create new and innovative organic compounds for various applications.
Used in Drug Development:
Tert-butyl2-(piperazin-1-yl)acetate is utilized in the development of new drugs, contributing to the advancement of pharmaceutical formulations and improving the efficacy and safety of medications.

Upstream product

• 110-85-0 piperazine 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 107-59-5 tert-Butyl chloroacetate 

Downstream Products

• 1620517-04-5 2-(4-(5-oxo-5-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenylamino)pentyl)piperazin-1-yl)acetic acid 
• 1620517-37-4 2-(4-(5-oxo-5-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenylamino)pentyl)piperazin-1-yl)acetic acid 
• 1620172-28-2 C₉₁H₁₅₇N₁₅O₁₈ 

Relevant academic research and scientific papers

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

PHOTOAFFINITY PROBES

Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photor

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Heteroaryl substituted dihydro pyrimidine compounds and their use in medicine

The invention relates to heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines, particularly application in medicines for treating and preventing hepatitis B. Particularly, the invention relates to compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, wherein the variables are defined in the specification. The invention also relates to application of the compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, hydrates, solvates or pharmaceutically acceptable salts thereof, especially application in medicines for treating and preventing hepatitis B.

Dihydropyrimidine compounds and their use in medicine

The invention relates to dihydropyrimidine compounds and application thereof in medicines, particularly application in medicines for treating and preventing hepatitis B. Particularly, the invention relates to compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, tautomerides, hydrates, solvates or pharmaceutically acceptable salts thereof, wherein the variables are defined in the specification. The invention also relates to application of the compounds disclosed as general formula (I) or (Ia), or enantiomers, diastereoisomers, tautomerides, hydrates, solvates or pharmaceutically acceptable salts thereof, especially application in medicines for treating and preventing hepatitis B.

Synthesis and structure-activity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles

With the aim of discovering a novel class of non-phosphorus-based fructose-1,6-bisphosphatase (FBPase) inhibitors, a series of 2,5-diphenyl-1,3,4-oxadiazoles were synthesized based on the hit compound (1) resulting from a high-throughput screening (HTS). Structure-activity relationship (SAR) studies led to the identification of several compounds with comparable inhibitory activities to AMP, the natural allosteric inhibitor of FBPase. Notably, compound 22 and 27b, bearing a terminal carboxyl or 1H-tetrazole, demonstrated remarkable inhibition to gluconeogenesis (GNG). In addition, both inhibition and binding mode to the enzyme were investigated by enzymatic kinetics and in silico experiments for representative compounds 16 and 22.

FULLERENE FILM AND FULLERENE POLYMER BOTH PRODUCED FROM FULLERENE DERIVATIVE AND PROCESSES FOR PRODUCING THESE

Disclosed is a fullerene film which can be easily formed by a wet process without deteriorating the intrinsic properties of a fullerene by using a fullerene derivative as a raw material. Also disclosed are a fullerene polymer, a method for producing a ful